1. Home
  2. GFUZ vs PHAR Comparison

GFUZ vs PHAR Comparison

Compare GFUZ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GFUZ

General Fusion Group Ltd. Common Shares

N/A

Current Price

$7.56

Market Cap

687.0M

Sector

Utilities

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

BUY

Current Price

$9.74

Market Cap

793.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
GFUZ
PHAR
Founded
2002
1988
Country
Canada
Netherlands
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
687.0M
793.4M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
GFUZ
PHAR
Price
$7.56
$9.74
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $34.35
AVG Volume (30 Days)
★ 98.6K
36.8K
Earning Date
12-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.92
Revenue Next Year
N/A
$8.85
P/E Ratio
★ N/A
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$6.08
$9.62
52 Week High
$11.00
$21.34

Technical Indicators

Market Signals
Indicator
GFUZ
PHAR
Relative Strength Index (RSI) 47.09 34.07
Support Level $7.55 $9.62
Resistance Level $8.77 $11.60
Average True Range (ATR) 0.49 0.40
MACD -0.07 -0.07
Stochastic Oscillator 25.00 1.93

Price Performance

Historical Comparison
GFUZ
PHAR

About GFUZ General Fusion Group Ltd. Common Shares

General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: